Literature DB >> 10481963

Use of diagnostic categories in urinary cytology in comparison with the bladder tumour antigen (BTA) test in bladder cancer patients.

M Takashi1, U Schenck, K Kissel, H Leyh, U Treiber.   

Abstract

In recent years the use of diagnostic categories for extragenital cytology has increasingly been discussed as an approach to improve the quality of reports. Diagnostic categories reflect the adequacy of the materials for interpretation and the presence or absence of cancer cells. There is a tendency to add intermediate groups as qualifying probably malignant cases or findings associated with a serious cancer risk. Since 1971 we have added one of the following to the final diagnosis in all cases: unsatisfactory for cytological diagnosis, negative for cancer, repeat test suggested, suspicious of cancer, and positive for cancer. To evaluate whether diagnostic categories are useful for comparison of cytological results with those of an alternative test, cytological data were compared with the results of the Bard bladder tumour antigen (BTA) test in voided urine from 119 patients (76 with and 43 without bladder cancer). The diagnostic categories enabled us to calculate sensitivities and specificities of cytology based on different thresholds or decision levels. The BTA test had significantly higher sensitivity (79%) and lower specificity (60%) than urinary cytology with three different thresholds in cytology results (sensitivities: 16-43%, specificities: 81-100%). The present findings suggest that diagnostic categories improve comparison of cytologic results with those of alternative screening and diagnostic aids such as the BTA test.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10481963     DOI: 10.1023/a:1007124724817

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  13 in total

Review 1.  Terminology. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial.

Authors:  U Schenck; A Herbert; D Solomon; N S Amma; R J Collins; S K Gupta; M Jimenez-Ayala; J Kobilková; M Nielsen; H Z Suprun
Journal:  Acta Cytol       Date:  1998 Jan-Feb       Impact factor: 2.319

2.  Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder.

Authors:  A Ianari; C N Sternberg; A Rossetti; A Van Rijn; A Deidda; D Giannarelli; V Pansadoro
Journal:  Urology       Date:  1997-05       Impact factor: 2.649

Review 3.  Current status of urinary cytology in the evaluation of bladder neoplasms.

Authors:  W M Murphy
Journal:  Hum Pathol       Date:  1990-09       Impact factor: 3.466

4.  Significance of the BTA test in bladder cancer: a multicenter trial. BTA Study Group Japan.

Authors:  N Miyanaga; H Akaza; S Kameyama; T Hachiya; S Ozono; M Kuroda; H Koga; K Koiso
Journal:  Int J Urol       Date:  1997-11       Impact factor: 3.369

5.  Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract.

Authors:  G A Carpinito; W M Stadler; J V Briggman; G W Chodak; P A Church; D L Lamm; P H Lange; E M Messing; R M Pasciak; G B Reservitz; R N Ross; D B Rukstalis; M F Sarosdy; M S Soloway; R P Thiel; N Vogelzang; C L Hayden
Journal:  J Urol       Date:  1996-10       Impact factor: 7.450

6.  Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer.

Authors:  H G Wiener; G P Vooijs; B van't Hof-Grootenboer
Journal:  Acta Cytol       Date:  1993 Mar-Apr       Impact factor: 2.319

7.  The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms.

Authors:  W M Murphy; I Rivera-Ramirez; C A Medina; N J Wright; Z Wajsman
Journal:  J Urol       Date:  1997-12       Impact factor: 7.450

8.  Initial evaluation of the bladder tumor antigen test in superficial bladder cancer.

Authors:  M A D'Hallewin; L Baert
Journal:  J Urol       Date:  1996-02       Impact factor: 7.450

9.  Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.

Authors:  M S Soloway; V Briggman; G A Carpinito; G W Chodak; P A Church; D L Lamm; P Lange; E Messing; R M Pasciak; G B Reservitz; D B Rukstalis; M F Sarosdy; W M Stadler; R P Thiel; C L Hayden
Journal:  J Urol       Date:  1996-08       Impact factor: 7.450

10.  Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer.

Authors:  M F Sarosdy; R W deVere White; M S Soloway; J Sheinfeld; M A Hudson; P F Schellhammer; M V Jarowenko; G Adams; B A Blumenstein
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

View more
  5 in total

1.  Critical evaluation of urinary markers for bladder cancer detection and monitoring.

Authors:  Shahrokh F Shariat; Jose A Karam; Yair Lotan; Pierre I Karakiewizc
Journal:  Rev Urol       Date:  2008

Review 2.  [Non-invasive urinary diagnosis of bladder cancer. What do we know?].

Authors:  I Kausch; A Böhle
Journal:  Urologe A       Date:  2003-04-11       Impact factor: 0.639

3.  Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysis.

Authors:  Aiye Guo; Xiuhua Wang; Lan Gao; Juan Shi; Changyi Sun; Zhen Wan
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

4.  A Comparison Between ThinPrep Monolayer and Cytospin Cytology for the Detection of Bladder Cancer.

Authors:  Ji Yong Kim; Hyung Jin Kim
Journal:  Korean J Urol       Date:  2014-06-16

5.  Urinary markers for bladder cancer.

Authors:  Zachary L Smith; Thomas J Guzzo
Journal:  F1000Prime Rep       Date:  2013-07-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.